Terlipressin acetate
规格
| Cas Number | 1884420-36-3 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | H2O : 100 mg/mL (74.21 mM; Need ultrasonic) DMSO : 50 mg/mL (37.11 mM; Need ultrasonic) |
| 过滤标签 | Vasopressin Receptor,GPCR/G Protein |
| 储存温度 | 充氩,干燥,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | 醋酸特利加压素是一种具有强效血管活性的血管紧张素类似物。醋酸特利加压素是一种高选择性血管紧张素 V1 受体激动剂，可降低脾脏血流量和门静脉压力，控制急性静脉曲张出血。T |
| 英文描述 |
Terlipressin acetate is a Vasotocin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective Vasotocin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research In Vitro Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells. Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R) Concentration: 25 nM Incubation Time: 24 hours, 48 hours, 72 hours Result: Significantly increased the proliferation of IEC-6 cells. In Vivo Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Vasotocin V1 receptor |